Revealing the true face behind the mask of ALK-positive anaplastic large cell lymphoma (ALCL)

Hannah Eisfeld1 · Stefan Kircher2 · Andreas Rosenwald2 · Ioannis Anagnostopoulos2 · Mathias Werner3 · Nikolaus Gaßler4 · Gunter Wolf5 · Lukas Lehmkuhl6 · Ulf Teichgräber7 · Falk Gühne8 · Andreas Darr8 · Martin Freesmeyer8 · Wolfram Weschenfelder9 · Gunther Hofmann9 · Ramazan Dalkılıc10 · Rolf Kalff10 · Andreas Hochhaus1 · Karin G. Schrenk1

Received: 16 August 2020 / Accepted: 28 August 2020 / Published online: 8 September 2020
© The Author(s) 2020

Dear Editor,

Anaplastic large cell lymphoma (ALCL) is the third most common peripheral T cell lymphoma [1] and is divided into anaplastic lymphoma receptor kinase (ALK)-positive and ALK-negative ALCL [2]. In 80% of ALK-positive ALCL, ALK is constitutively activated as a result of nucleophosmin (NPM)-ALK translocation. ALK belongs to the insulin receptor superfamily [3, 4]. Whereas the 5-year overall survival in ALK-positive ALCL is 70%, patients with ALK-negative ALCL have a 5-year survival of 32–50% [1, 5, 6]. On histology, ALCL shows large pleomorphic neoplastic cells with often horseshoe-shaped nuclei and strong expression of CD30, a cytokine receptor from the tumor necrosis factor receptor family [7, 8]. However, besides these characteristic findings, there is a broad range of morphological variations [8, 9].

We present an unusual case of a 38-year-old female patient with challenging diagnostic workup of an ALK-positive ALCL due to the variable histology and clinical course of this lymphoma. The patient initially complained of lower back pain and fever. FDG-potassium emission tomography and computerized tomography (PET-CT) of the thorax and abdomen revealed multiple bone lesions (Fig. 1a, b). The patient had an unremarkable medical and family history and no occurrence of B-symptoms. Clinical examination showed no abnormalities. All other examinations including bronchoscopy, gynecologic assessment, gastroscopy, colonoscopy, and abdominal ultrasound did not reveal any abnormalities. The laboratory results were within normal limits except elevated C-reactive protein (CRP) levels with 56.9 mg/l (normal range < 7.5 mg/l). A CT-guided core needle biopsy of an osteolytic lesion of the left iliac bone was performed. The histopathologic results showed an infectious or inflammatory process. No malignancies could be diagnosed; however, CD30-positive cells were found at low frequency, which could not be further evaluated due to the scarcity of the available tissue (Fig. 1c). A second bone biopsy of this lesion revealed metaplastic woven bone with chronic inflammatory infiltration, consistent with chronic recurrent multifocal osteomyelitis (CRMO) (Fig. 1f). Bisphosphonates and corticosteroid...
therapy was commenced. Because of refractory pain, tumor necrosis alpha inhibitor infliximab was given. Magnetic resonance imaging (MRI) scan revealed a L2 fracture (Fig. 1j). Therefore, dorsal stabilizing surgery was performed. Unexpectedly, the bone histology revealed an ALK-positive ALCL (Fig. 1g–i).

Seven months after her first visit, the diagnosis was finally made. The patient reported loss of weight over the last 14 months of 18 kg of body weight. She was still suffering from pain in the hip and the lumbar spine and had upper abdominal spasms. A PET-CT was performed, revealing hypermetabolic paravertebral lesions in the region of the resected L2 with infiltration of the psoas muscle (Fig. 1m, o) and in the pancreas (Fig. 1k). However, all the previously known osteolytic lesions had disappeared (Fig. 1d, e). After pre-phase chemotherapy, the patient received six cycles of bi-weekly CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone). After the sixth cycle, PET-CT showed a complete response, Deauville-5P-response score 1 (Fig. 1l, n, p). The patient has been in complete remission for 33 months.

Since the discovery of ALCL by Stein et al. [10] due to the characteristic staining with the anti-Ki-1-antibody labeling CD30, high variability in the morphologic appearance of ALCL has been recognized [9, 10]. The major histological classification includes the common type, the small cell type, and the lymphohistiocytic variant of ALCL. Other variants resemble Hodgkin’s disease with giant cells, signet-ring cell tumors, sarcoidosis, sarcoma, or inflammation with a high amount of neutrophil and eosinophil granulocytes [9]. Moreover, approximately 30% of ALK-positive ALCLs have a mixture of several histological variants [9].

---

**Fig. 1** Upper and middle panel: initial manifestations of ALK-positive ALCL. a PET and b CT imaging demonstrating hypermetabolic bone lesions in the left iliac bone. Initial histology with c few CD30-positive cells (× 200 magnification) and f metaplastic woven bone as well as chronic inflammatory infiltration (× 20 magnification), consistent with the diagnosis of chronic recurrent multifocal osteomyelitis (CRMO). d PET and e CT scan after therapy with steroids and infliximab. All initial hypermetabolic bone lesions had disappeared. j MRI scan of fractured L2. Histology revealed the diagnosis of ALK-positive anaplastic large cell lymphoma. g Hematoxylin staining (× 400 magnification), h ALK staining (× 400 magnification), and i CD30 staining (× 200 magnification). Lower panel: PET imaging before and after treatment with chemotherapy. New hypermetabolic lesions were found k in the pancreas and m, o paravertebral in the region of the resected L2 vertebral body with infiltration into the psoas muscle. l, n, p After treatment with 6 cycles of combination chemotherapy according to the CHOEP protocol complete remission was achieved (Deauville-5P-response score 1)
This case shows the difficulties in diagnosing ALK-positive ALCL due to the variable clinical course including bone infiltration. A major challenge is a histological diagnosis since anaplastic large cell lymphoma may present with heterogeneous morphology, expansion of inflammatory cells, and few CD30-positive cells, especially if limited biopsy material is warranted, contributing to delayed diagnosis. In patients with bone lesions and unspecified histological result, ALCL should be considered with high priority in differential diagnosis.

Funding Open Access funding provided by Projekt DEAL.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Vu K, Ai W (2018) Update on the treatment of anaplastic large cell lymphoma. Curr Hematol Malig Rep 13(2):135–141
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon
3. Werner MT, Zhao C, Zhang Q, Wasik MA (2017) Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. Blood 129(7):823–831
4. Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, Witte DP (1997) ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14(18):2175–2188
5. Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124–4130
6. Happgood G, Savage KJ (2015) The biology and management of systemic anaplastic large cell lymphoma. Blood 126(1):17–25
7. Bennani-Baiti N, Ansell S, Feldman AL (2016) Adult systemic anaplastic large cell lymphoma: recommendations for diagnosis and management. Expert Rev Hematol 9(2):137–150
8. Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B (2000) CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic and clinical features. Blood 96(12):3681–3695
9. Tsuyma N, Sakamoto K, Sakata S, Dobashi A, Takeuchi K (2017) Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. J Clin Exp Hematop 57(3):120–142
10. Stein H, Mason DY, Gerdes J, O’Connor N, Wainscoat J, Pullesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwartz R (1985) The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66(4):848–858

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.